|
ES2524356T3
(es)
|
2010-07-22 |
2014-12-05 |
Gilead Sciences, Inc. |
Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
EP3197459B1
(en)
*
|
2014-09-28 |
2025-02-12 |
Huahui Health Ltd. |
Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport
|
|
TWI687432B
(zh)
|
2014-10-29 |
2020-03-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
|
CA2981503C
(en)
|
2015-03-31 |
2023-09-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
PE20180690A1
(es)
|
2015-04-27 |
2018-04-23 |
Intercept Pharmaceuticals Inc |
Composiciones de acido obeticolico y metodos de uso
|
|
DK3785717T3
(da)
|
2015-09-16 |
2022-03-21 |
Gilead Sciences Inc |
Fremgangsmåder til behandling af coronaviridae-infektioner
|
|
WO2017189663A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US10080741B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
WO2017189651A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US10144729B2
(en)
|
2016-05-18 |
2018-12-04 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
WO2017201152A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017201155A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
|
|
NZ748641A
(en)
|
2016-06-13 |
2020-04-24 |
Gilead Sciences Inc |
Fxr (nr1h4) modulating compounds
|
|
CA2968836C
(en)
|
2016-06-13 |
2025-09-02 |
Gilead Sciences, Inc. |
FXR MODULATING COMPOUNDS (NR1H4)
|
|
AU2017318601B2
(en)
|
2016-09-02 |
2020-09-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
KR102399254B1
(ko)
*
|
2016-09-28 |
2022-05-17 |
아이거 바이오파마슈티컬스 인코포레이티드 |
비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
|
|
MX2019003790A
(es)
|
2016-10-04 |
2019-09-26 |
Enanta Pharm Inc |
Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
|
|
KR20230010826A
(ko)
|
2016-10-14 |
2023-01-19 |
프리시젼 바이오사이언시스 인코포레이티드 |
B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
|
|
WO2018081285A1
(en)
|
2016-10-26 |
2018-05-03 |
Enanta Pharmaceuticals, Inc. |
Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
|
|
CN108017636A
(zh)
*
|
2016-11-04 |
2018-05-11 |
合帕吉恩治疗公司 |
作为fxr调节剂的含氮杂环化合物
|
|
TW202510891A
(zh)
|
2017-01-31 |
2025-03-16 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
US10682368B2
(en)
*
|
2017-03-14 |
2020-06-16 |
Gilead Sciences, Inc. |
Methods of treating feline coronavirus infections
|
|
SI4122464T1
(sl)
|
2017-03-28 |
2024-07-31 |
Gilead Sciences, Inc. |
Terapevtske kombinacije za zdravljenje bolezni jeter
|
|
WO2018178260A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
CA3059777C
(en)
|
2017-05-01 |
2023-02-21 |
Gilead Sciences, Inc. |
Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
|
WO2019014247A1
(en)
|
2017-07-11 |
2019-01-17 |
Gilead Sciences, Inc. |
COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
KR102114394B1
(ko)
|
2017-08-30 |
2020-05-22 |
경희대학교 산학협력단 |
벤조페논 유도체, 이의 제조방법 및 이를 포함하는 b형간염 치료용 약학적 조성물
|
|
US10689391B2
(en)
|
2017-12-12 |
2020-06-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
EP3728283B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
WO2019123339A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CN110128432B
(zh)
|
2018-02-02 |
2021-03-02 |
广东东阳光药业有限公司 |
含氮三环化合物及其在药物中的应用
|
|
CR20200347A
(es)
|
2018-02-13 |
2020-09-23 |
Gilead Sciences Inc |
Inhibidores pd-1/pd-l1
|
|
WO2019160813A1
(en)
|
2018-02-14 |
2019-08-22 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
JP7050165B2
(ja)
|
2018-02-26 |
2022-04-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
TWI712412B
(zh)
|
2018-04-19 |
2020-12-11 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
SG11202012425QA
(en)
|
2018-07-13 |
2021-01-28 |
Gilead Sciences Inc |
Pd-1/pd-l1 inhibitors
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
WO2020086556A1
(en)
|
2018-10-24 |
2020-04-30 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
US11203591B2
(en)
|
2018-10-31 |
2021-12-21 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds
|
|
PT3911647T
(pt)
|
2019-01-15 |
2024-03-04 |
Gilead Sciences Inc |
Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
|
|
JP2022519906A
(ja)
|
2019-02-19 |
2022-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｆｘｒアゴニストの固体形態
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
EP3934757B1
(en)
|
2019-03-07 |
2023-02-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
WO2020231917A1
(en)
|
2019-05-13 |
2020-11-19 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
WO2020263830A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
|
CA3139750A1
(en)
*
|
2019-07-18 |
2021-01-21 |
Jacky Vonderscher |
Improved treatment using eyp001
|
|
ES2968931T3
(es)
|
2019-07-18 |
2024-05-14 |
Enyo Pharma |
Efecto sinérgico de eyp001 e ifn-alfa pegilado para el tratamiento de la infección por hbv
|
|
US20220257619A1
(en)
|
2019-07-18 |
2022-08-18 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
EP3999101A1
(en)
*
|
2019-07-18 |
2022-05-25 |
ENYO Pharma |
Method for decreasing adverse-effects of interferon
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
DK4037708T3
(da)
|
2019-09-30 |
2024-09-30 |
Gilead Sciences Inc |
HBV-vacciner og fremgangsmåder til at behandle HBV
|
|
WO2021108974A1
(en)
|
2019-12-03 |
2021-06-10 |
Gannex Pharma Co., Ltd |
Compounds for modulating activity of fxr and uses thereof
|
|
DK4069729T3
(da)
|
2019-12-06 |
2025-04-07 |
Prec Biosciences Inc |
Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
|
|
IL294032A
(en)
|
2019-12-24 |
2022-08-01 |
Carna Biosciences Inc |
Compounds that regulate diacylglycerol kinase
|
|
WO2021144330A1
(en)
*
|
2020-01-15 |
2021-07-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
JP2023512656A
(ja)
|
2020-01-27 |
2023-03-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
|
|
KR20220153619A
(ko)
|
2020-03-12 |
2022-11-18 |
길리애드 사이언시즈, 인코포레이티드 |
1'-시아노 뉴클레오사이드의 제조 방법
|
|
WO2021188695A1
(en)
|
2020-03-18 |
2021-09-23 |
Metacrine, Inc. |
Formulations of a farnesoid x receptor agonist
|
|
IL296532A
(en)
|
2020-03-18 |
2022-11-01 |
Metacrine Inc |
Crystal forms of farnesoid x receptor agonist
|
|
WO2021188959A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
CA3172483A1
(en)
|
2020-04-06 |
2021-10-14 |
Scott Ellis |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
|
KR20200049728A
(ko)
|
2020-04-24 |
2020-05-08 |
경희대학교 산학협력단 |
벤조페논 유도체, 이의 제조방법 및 이를 포함하는 b형간염 치료용 약학적 조성물
|
|
TW202203941A
(zh)
|
2020-05-29 |
2022-02-01 |
美商基利科學股份有限公司 |
瑞德西韋之治療方法
|
|
PE20230618A1
(es)
|
2020-06-24 |
2023-04-14 |
Gilead Sciences Inc |
Analogos de nucleosido de 1'-ciano y usos de los mismos
|
|
EP4192474B1
(en)
|
2020-08-07 |
2025-09-10 |
Gilead Sciences, Inc. |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
IL300412A
(en)
|
2020-08-24 |
2023-04-01 |
Gilead Sciences Inc |
Phospholipid compounds and their uses
|
|
IL300453A
(en)
|
2020-08-27 |
2023-04-01 |
Gilead Sciences Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
WO2022076683A1
(en)
*
|
2020-10-07 |
2022-04-14 |
Intercept Pharmaceuticals, Inc. |
Methods of treating coronaviral infection with obeticholic acid
|
|
TW202344257A
(zh)
|
2020-10-16 |
2023-11-16 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
KR20230154806A
(ko)
|
2021-01-14 |
2023-11-09 |
엔요 파마 |
Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
|
|
CN116685321A
(zh)
*
|
2021-01-14 |
2023-09-01 |
埃尼奥制药公司 |
治疗慢性肾病的方法
|
|
US20240239775A1
(en)
*
|
2021-04-16 |
2024-07-18 |
Qingdao Ruiji Medical Technology Co., Ltd. |
Fxr regulator, preparation method therefor, pharmaceutical composition thereof and use thereof
|
|
WO2022241134A1
(en)
|
2021-05-13 |
2022-11-17 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
WO2022251318A1
(en)
|
2021-05-26 |
2022-12-01 |
Gilead Sciences, Inc. |
Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
AU2022328698B2
(en)
|
2021-08-18 |
2025-02-20 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
JP2025014084A
(ja)
*
|
2021-12-07 |
2025-01-29 |
慶應義塾 |
ウイルス増殖抑制剤
|
|
KR20240154647A
(ko)
|
2022-03-02 |
2024-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
바이러스성 감염 치료를 위한 화합물 및 방법
|
|
KR20240154646A
(ko)
|
2022-03-02 |
2024-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
바이러스성 감염 치료를 위한 화합물 및 방법
|
|
KR20240155326A
(ko)
|
2022-03-03 |
2024-10-28 |
길리애드 사이언시즈, 인코포레이티드 |
항바이러스 화합물 및 이의 제조와 사용 방법
|
|
JP2025508941A
(ja)
|
2022-03-03 |
2025-04-10 |
ギリアード サイエンシーズ， インコーポレイテッド |
抗ウイルス化合物並びにその作製及び使用方法
|
|
EP4506007A4
(en)
*
|
2022-04-06 |
2025-10-22 |
Shaperon Inc |
COMPOSITION FOR THE PREVENTION OR TREATMENT OF PULMONARY FIBROSIS, COMPRISING TAURODEOXYCHOLIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT
|
|
US20240009220A1
(en)
|
2022-06-06 |
2024-01-11 |
Gilead Sciences, Inc. |
Methods for treatment of viral infections
|
|
WO2024006376A1
(en)
|
2022-06-29 |
2024-01-04 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
EP4547665A1
(en)
|
2022-06-30 |
2025-05-07 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
|
WO2024173458A1
(en)
|
2023-02-16 |
2024-08-22 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
AU2024330988A1
(en)
|
2023-08-31 |
2026-02-19 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
US20250090537A1
(en)
|
2023-08-31 |
2025-03-20 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
WO2025054278A1
(en)
|
2023-09-06 |
2025-03-13 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US20250109157A1
(en)
|
2023-09-28 |
2025-04-03 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|